Get the latest news, insights, and market updates on LPTX (Leap Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Cypherpunk Technologies (CYPH): How a Radical Crypto Pivot Is Shaping Its Current Valuation
Cypherpunk Technologies (CYPH) is making headlines as it pivots from its biotech roots to a digital asset-focused future. The company is rebranding from Leap Therapeutics and investing heavily in Zcash after securing substantial funding. This bold transformation is shaking up market conversations. See our latest analysis for Cypherpunk Technologies. Cypherpunk Technologies’ dramatic pivot and fresh capital sent its share price soaring 284% over the past week and 182% in the past month, even... Nov 14, 2025 - $LPTX
Winklevoss-backed stock halted multiple times after wild 550% rally
Trading of Leap Therapeutics (Nasdaq: LPTX), the biotech firm transforming into a Zcash treasury firm, halted multiple times on Nasdaq after the stock jumped more than 550% to hit the intraday high of $2.48 on Nov. 12. Leap Therapeutics recently secured $58.88 million in a private placement ... Nov 12, 2025 - $LPTX
Leap Therapeutics Rebrands as Cypherpunk Technologies to Focus on Zcash
On Nov. 12, Nasdaq-listed Leap Therapeutics rebranded to Cypherpunk Technologies Inc. This comes as the company focuses on pursuing a digital asset strategy by accumulating ZEC ZEC $512.1 24h volatility: 0.0% Market cap: $8.49 B Vol. 24h: $1.71 B , a privacy coin tied to the Zcash network. It is ... Nov 12, 2025 - $LPTX
Billionaire twins–backed stock surges 100% after buying $50M ‘encrypted Bitcoin’
Leap Therapeutics (Nasdaq: LPTX), a Cambridge, Massachusetts-based biotechnology company, is going to rebrand itself into Cypherpunk Technologies Inc., the company announced on Nov. 12. Cypherpunk will begin trading under its new ticker symbol CYPH tomorrow onward. The goal is ... Nov 12, 2025 - $LPTX
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior Oct 20, 2025 - $LPTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple